Ultragenyx Pharmaceutical (MEX:RARE) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RARE Ultragenyx Pharmaceutical Inc MEX:RARE
69 GF Score
Price MXN1,150.56
GF Value MXN1,861.65
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MEX:RARE
69GF Score
Ultragenyx Pharmaceutical Inc MEX:RARE
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,150.56 is trading 38.2% below its estimated GF Value™ of MXN1,861.65.

Key valuation signals for MEX:RARE:

  • Short Ratio:
  • GF Value™: MXN1,861.65 vs. price of MXN1,150.56 (38.2% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
69GF Score

Get the complete analysis for MEX:RARE

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.56
Price
MXN1,861.65
GF Value